Eichorn Laura G. 4
4 · Imago BioSciences, Inc. · Filed Jan 5, 2023
Insider Transaction Report
Form 4
Eichorn Laura G.
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2023-01-03$2.52/sh+22,950$57,834→ 232,284 total - Exercise/Conversion
Common Stock
2023-01-03$4.20/sh+12,400$52,080→ 244,684 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-01-03−22,950→ 0 totalExercise: $2.52From: 2021-01-01Exp: 2027-03-28→ Common Stock (22,950 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2023-01-03−12,400→ 11,409 totalExercise: $4.20Exp: 2031-02-04→ Common Stock (12,400 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2023-01-03−1,769→ 101,231 totalExercise: $22.76Exp: 2031-11-16→ Common Stock (1,769 underlying) - Exercise/Conversion
Common Stock
2023-01-03$22.76/sh+1,769$40,262→ 246,453 total
Footnotes (3)
- [F1]Reflects the adjusted total which includes the purchase of 1,597 shares under the Imago Employee Stock Purchase Plan on November 30, 2022.
- [F2]One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from November 12, 2020 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
- [F3]25% of the shares subject to the option vest on the first anniversary measured from November 17, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.